Endocrine Research

GHRH Analogs: The DPP-4 Resistance Strategy

Native GHRH is a 44-amino acid peptide cleaved rapidly by dipeptidyl peptidase-4 (DPP-4), giving it a plasma half-life of approximately 7 minutes. This is too short for clinical or research applications. Modified GHRH analogs solve this through different strategies. Sermorelin is GHRH(1-29) — the minimal active sequence — which retains receptor binding but has only marginally improved stability. Tesamorelin takes the full 44-amino acid sequence and adds a trans-3-hexenoyl group at the N-terminus, blocking DPP-4 cleavage at the critical Tyr1-Ala2 site. This modification extends plasma half-life to roughly 26-38 minutes — a fivefold improvement that makes pharmacological dosing feasible. CJC-1295 takes a different approach: it includes a Drug Affinity Complex (DAC) moiety that binds covalently to serum albumin, extending half-life to multiple days. The three compounds occupy the same receptor but differ substantially in pharmacokinetic profile, which is why they're studied in different research contexts.

Ghrelin Mimetics: The Parallel Circuit

Ghrelin signaling runs through GHS-R1a (growth hormone secretagogue receptor 1a) — a Gq-coupled receptor expressed on pituitary somatotrophs and arcuate hypothalamic neurons. The pathway is parallel to but distinct from GHRH signaling. The first-generation ghrelin mimetics — GHRP-2 (pralmorelin) and GHRP-6 — are hexapeptides with strong GH-releasing activity but limited receptor selectivity, also affecting prolactin, cortisol, and aldosterone secretion. Ipamorelin represents the second-generation refinement: a pentapeptide with improved GHS-R1a selectivity that minimizes effects on prolactin and cortisol. Hexarelin is structurally similar to GHRP-6 with additional cardioprotective effects studied separately from the GH axis context. The selectivity differences matter for research — Ipamorelin is preferred when isolating GH effects from broader endocrine perturbation, while GHRP-2/6 are studied when the parallel hormonal effects are themselves the research interest.

GHRH Plus Ghrelin: Synergistic Pulses

GHRH analogs and ghrelin mimetics act through different receptors converging on the same somatotrophs — and combining them produces more than additive GH release. The synergy is studied in research models examining GH pulse architecture: GHRH primes the somatotroph through cAMP/PKA signaling, while ghrelin mimetics independently activate Ca²⁺ release through Gq/PLC pathways. The combined signaling amplifies GH secretion beyond what either compound produces alone. CJC-1295 + Ipamorelin combinations are among the most-studied research stack configurations for this reason, though "research stack" usage in non-controlled contexts has outpaced formal pharmacokinetic characterization of the combinations.

Research Models Commonly Used

Standard in vivo endocrine peptide research uses GHRH receptor knockout (Ghrhr-deficient lit/lit mice) for receptor-specific work, hypophysectomized rats for studying pituitary-independent effects, fasted rodents for ghrelin pulse characterization, and aged C57BL/6 mice for studying somatopause biology. HIV-associated lipodystrophy research uses both human clinical cohorts and rodent models with antiretroviral exposure. In vitro work uses primary rat pituitary cell cultures for direct somatotroph studies, GH3 immortalized rat pituitary cells for screening, and HEK293 cells transfected with human GHRH receptor or GHS-R1a for receptor pharmacology. GH pulse measurement typically uses serial blood sampling protocols (every 10-15 minutes for 6-24 hours) with sensitive immunoassays, deconvolution analysis to characterize pulse amplitude and frequency, and IGF-1 as a longer-term integrated readout.

Frequently Asked Questions

Reference Points for Further Reading

For Tesamorelin clinical evidence, the 2010 Falutz et al. publications in NEJM and subsequent Theratechnologies-sponsored studies provide the Phase 3 data foundation. The 2026 ScienceDirect meta-analysis (S1871403X26000025) covers the consolidated evidence base across five RCTs. The Theratechnologies regulatory documentation for EGRIFTA WR (March 2025 FDA approval) is publicly available. For GHRH and ghrelin pharmacology more broadly, the Bowers reviews on growth hormone secretagogues provide the historical mechanistic foundation; Smith's reviews cover the discovery and characterization of GHS-R1a. For DPP-4 resistance strategies, the Demuth et al. publications on enzyme-substrate engineering remain standard references. The Sonntag and Murialdo reviews on the somatopause and aged GH/IGF-1 axis provide context for aging-related applications of the GH research field.

All compounds in this catalog are intended for in vitro and preclinical research use only. None are approved by the FDA for therapeutic use in humans, with the exception of Tesamorelin (marketed as EGRIFTA, EGRIFTA SV, and EGRIFTA WR by Theratechnologies) which is FDA-approved for the specific indication of HIV-associated lipodystrophy. Sermorelin previously had FDA approval for pediatric growth hormone deficiency but is no longer marketed in the US under that approval. Clinical and regulatory information referenced on this page describes research conducted with approved pharmaceutical products and is provided as scientific context, not as claims for the research compounds offered here.